PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-34.85%
Negative net income growth while VET stands at 18.49%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
10.84%
D&A growth well above VET's 1.74%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
28.68%
Some yoy growth while VET is negative at -735.18%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
95.11%
Well above VET's 14.80% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
95.11%
Growth well above VET's 14.80%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-66.94%
Negative yoy while VET is 156.36%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
2.36%
Operating cash flow growth below 50% of VET's 17.63%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
-39.96%
Negative yoy CapEx while VET is 66.15%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.36%
We have some outflow growth while VET is negative at -453.55%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
-37.33%
We reduce yoy invests while VET stands at 49.11%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-834.30%
We cut debt repayment yoy while VET is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-92.96%
Negative yoy issuance while VET is 16.94%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
68.61%
Buyback growth of 68.61% while VET is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.